clinical trial · NCT06594991
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Advanced MelanomaFianlimabCemiplimabIpilimumab
brief summary
The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.
started
Sep 10, 2024
primary completion
Sep 1, 2027
completion
Sep 1, 2027
last updated
Oct 7, 2026
official title
A Phase 2 Study of Fianlimab, Cemiplimab, and Ipilimumab in Anti-PD-1 Refractory Melanoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol